Thymic carcinoma is a part of the malignant spectrum of thymic epithelial tumors, along with malignant thymomas and neuroendocrine carcinomas.
On this page:
Epidemiology
Patients are typically 50 to 70 years of age at presentation 9.
Pathology
The incidence of paraneoplastic syndromes is thought to be low. At least 10 different histologic variants have been described 4. The most common subtypes are squamous cell carcinoma and lymphoepithelial-like carcinoma 1.
Classification
The WHO classification of thymic tumors (5th ed.) divides thymic carcinomas into the following morphological entities 10:
-
squamous cell carcinomas
squamous cell carcinoma, not otherwise specified
basaloid carcinoma
lymphoepithelial carcinoma
NUT carcinoma of the thorax
-
salivary gland-like carcinomas
mucoepidermoid carcinoma
clear cell carcinoma
sarcomatoid carcinoma
-
adenocarcinomas
adenocarcinoma, not otherwise specified
low-grade papillary adenocarcinoma
thymic carcinoma with adenoid cystic carcinoma-like features
enteric-type adenocarcinoma
adenosquamous carcinoma
undifferentiated carcinoma
thymic carcinoma, not otherwise specified
The category of thymic carcinoma NOS includes entities also known as hepatoid carcinoma, rhabdoid carcinoma, undifferentiated large cell carcinoma associated with Castleman disease-like reaction, and sebaceous carcinoma, although these fall under the same morphology code in this classification. Carcinosarcoma is a subtype of sarcomatoid carcinoma.
Radiographic features
CT
Useful features for differential from more benign thymic epithelial tumors include 1:
larger 5 and highly aggressive anterior mediastinal mass
areas of necrosis, hemorrhage, calcification, or cyst formation
gross invasion of contiguous mediastinal structures and wide spread to involve distant intrathoracic sites
high incidence of extrathoracic metastases
Nuclear medicine
FDG PET-CT may be useful in differentiating thymic carcinoma from other thymic neoplasms, thymic hyperplasia, and normal physiologic uptake. The standardized uptake value (SUV) for thymic carcinoma is considered to be significantly greater than that for invasive or noninvasive thymoma, often with an SUV cutoff point of 5.0, thymic carcinoma can be differentiated from thymoma with reasonably high sensitivity (84.6%), specificity (92.3%), and accuracy (88.5%) 6.
Treatment and prognosis
They are often associated with a poor prognosis.
Differential diagnosis
For an invasive anterior mediastinal mass lesion consider:
primary mediastinal lymphoma with invasive spread: lack infiltration
lung cancer with mediastinal invasion